BioCorRx Inc
OTC:BICX

Watchlist Manager
BioCorRx Inc Logo
BioCorRx Inc
OTC:BICX
Watchlist
Price: 0.4 USD Market Closed
Market Cap: $9.5m

Operating Margin

-1 640.5%
Current
Improving
by 9 380.6%
vs 3-y average of -11 021%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 640.5%
=
Operating Income
$-5.1m
/
Revenue
$313.1k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 640.5%
=
Operating Income
$-5.1m
/
Revenue
$313.1k

Peer Comparison

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-1 640.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

BioCorRx Inc
Glance View

Market Cap
9.5m USD
Industry
Health Care

BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

BICX Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 640.5%
=
Operating Income
$-5.1m
/
Revenue
$313.1k
What is BioCorRx Inc's current Operating Margin?

The current Operating Margin for BioCorRx Inc is -1 640.5%, which is above its 3-year median of -11 021%.

How has Operating Margin changed over time?

Over the last 3 years, BioCorRx Inc’s Operating Margin has increased from -9 066.7% to -1 640.5%. During this period, it reached a low of -66 526% on Dec 31, 2024 and a high of -1 640.5% on Jul 30, 2025.

Back to Top